世界各国のリアルタイムなデータ・インテリジェンスで皆様をお手伝い

次世代抗体治療薬の世界市場に関する洞察と2028年までの予測


Global Next Generation Antibody Therapeutics Market Insights and Forecast to 2028

市場の分析と洞察。次世代抗体治療薬の世界市場 COVID-19のパンデミックとスペイン・ウクライナ戦争の影響により、2022年に1億2257.15万米ドルと推定される次世代抗体治療薬の世界市場は、2028年までに3億9424.4... もっと見る

 

 

出版社 出版年月 電子版価格 言語
QYResearch
QYリサーチ
2022年9月27日 US$4,900
シングルユーザライセンス
ライセンス・価格情報
注文方法はこちら
英語

※当ページの内容はウェブ更新時の情報です。
最新版の価格やページ数などの情報についてはお問合せください。

日本語のページは自動翻訳を利用し作成しています。
実際のレポートは英文のみでご納品いたします。


 

サマリー

市場の分析と洞察。次世代抗体治療薬の世界市場
COVID-19のパンデミックとスペイン・ウクライナ戦争の影響により、2022年に1億2257.15万米ドルと推定される次世代抗体治療薬の世界市場は、2028年までに3億9424.45万米ドルの修正規模に達すると予測され、予測期間2022~2028年に年率21.51%で成長するとされています。

次世代抗体治療薬のアメリカ市場は、2022年の7億3624万米ドルから、2022年から2028年の予測期間中にCAGR18.38%で増加し、2028年には2億25678万米ドルに達すると予測されます。
次世代抗体治療薬のヨーロッパ市場は、2022年の2億2,840万米ドルから、2022年から2028年の予測期間中にCAGR25.72%で増加し、2028年には9億1,950万米ドルに達すると予測されます。
次世代抗体治療薬の日本市場は、2022年の1億1542万米ドルから2028年には3億3761万米ドルに増加し、予測期間中にCAGR19.36%で到達すると予測されます。
次世代抗体治療薬の世界的な主要企業には、ロシュ、アムジェン、武田薬品、ファイザー、シーゲン社、ADCセラピューティックSA、アステラス、第一三共、イミュノミクス(ギリアド)などが含まれます。2021年、世界の上位5社の売上高シェアは約88.78%でした。

レポートの内容
本レポートでは、次世代抗体治療薬の世界市場規模を概観しています。2017年~2021年の歴史的な市場収益データ、2022年の予測、2028年までのCAGRの予測により、世界市場の動向を分析します。
次世代抗体治療薬の主要生産者を調査し、主要地域と国の収益も提供します。次世代抗体治療薬の今後の市場可能性のハイライトと、この市場を様々なセグメントとサブセグメントに分けて予測するための主要地域/国に焦点を当てます。米国、カナダ、メキシコ、ブラジル、日本、中国、韓国、東南アジア、インド、ドイツ、英国、イタリア、中東、アフリカ、その他の国々の国別データおよび市場価値分析。

本レポートでは、2017年から2022年までのデータをもとに、次世代抗体治療薬の収益、主要企業の市場シェア、業界ランキングに焦点を当てます。世界の次世代抗体治療薬市場における主要なステークホルダーを特定し、その競争環境と市場ポジショニングを最近の動向とセグメント別収益に基づき分析します。本レポートは、ステークホルダーが競争環境を理解し、より多くの洞察を得て、ビジネスや市場戦略をより良い方法で位置づけるのに役立ちます。

本レポートでは、2017年から2028年までのタイプ別、アプリケーション別のセグメントデータ、収益、成長率などを分析しています。次世代抗体治療薬の収益、予測成長動向、生産技術、アプリケーション、エンドユーザー産業の市場規模を評価・予測。
ロシュ、アムジェン、武田薬品、ファイザー、セーゲン社、ADCセラピューティックSA、アステラス、第一三共、イムノメディックス(ギリアド)など、世界の主要企業の説明的な企業プロフィール。

会社別
ロシュ
アムジェン
ファイザー
武田薬品工業
第一三共
セーゲン
アステラス製薬
イムノメディックス
GSK
イムノコア
ADCセラピューティック

タイプ別セグメント
抗体薬物複合体(ADC)
二重特異性抗体(BsAb)

用途別セグメント

血友病
その他の非癌性疾患

地域別
北アメリカ
米国
カナダ
メキシコ
アジア・パシフィック
中国
日本
韓国
インド
東南アジア
その他のアジア
欧州
ドイツ
フランス
英国
イタリア
スペイン
その他の欧州
南米
ブラジル
アルゼンチン
南米のその他
中近東・アフリカ
中東
アフリカ

各章の概要
第1章:レポートスコープ、市場セグメント(製品タイプ、アプリケーションなど)別の市場規模、将来の発展可能性などのエグゼクティブサマリーを紹介します。市場の現状と短期、中期、長期の展開の可能性を高次元で把握することができます。
第2章 次世代抗体治療薬の世界レベルおよび地域レベルでの収益各地域とその主要国の市場規模や発展可能性を定量的に分析し、世界各国の市場発展や今後の発展展望、市場スペース、生産能力などを紹介しています。また、市場のダイナミクス、市場の最新動向、市場の推進要因と制限要因、業界各社が直面する課題とリスク、業界の関連政策の分析についても紹介しています。
第3章:次世代抗体治療薬企業の競争環境、収益、市場シェア、業界ランキング、最新の開発計画、M&A情報などを詳細に分析。
第4章:読者が異なる市場セグメントでブルーオーシャン市場を見つけることができるように、タイプ別の様々な市場セグメントの分析、収益、各市場セグメントの開発ポテンシャルをカバーする情報を提供します。
第5章:読者が異なる下流市場のブルーオーシャン市場を見つけるのを助けるために、アプリケーション別の様々な市場セグメントの分析、各市場セグメントの収益、および開発ポテンシャルをカバーすることを提供します。
第6章:北米のタイプ別、アプリケーション別、国別、各セグメントごとの収益。
第7章:ヨーロッパ:タイプ別、アプリケーション別、国別、各セグメントごとの収益。
第8章:アジア太平洋地域:タイプ別、アプリケーション別、地域別、セグメント別売上。
第9章:南米:タイプ別、アプリケーション別、国別、各セグメントごとの収益。
第10章:中東・アフリカ:タイプ別、アプリケーション別、国別、セグメント別売上。
第11章:主要企業のプロフィールを提供し、製品の説明や仕様、次世代抗体治療薬の収益、総利益、最近の開発など、市場の主要企業の基本状況を詳細に紹介します。
第12章 アナリストの視点/結論

ページTOPに戻る


目次

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1
1.2.2 Antibody Drug Conjugate (ADC) 3
1.2.3 Bispecific Antibody (BsAb) 3
1.3 Market by Application 4
1.3.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 5
1.3.2 Cancer 6
1.3.3 Haemophilia 7
1.3.4 Other Non-Cancer Diseases 8
1.4 Study Objectives 9
1.5 Years Considered 10
2 Global Growth Trends 11
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2017-2028) 11
2.2 Next Generation Antibody Therapeutics Growth Trends by Region 12
2.2.1 Next Generation Antibody Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 12
2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2017-2022) 13
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2023-2028) 14
2.3 Next Generation Antibody Therapeutics Market Dynamics 15
2.3.1 Next Generation Antibody Therapeutics Industry Trends 15
2.3.2 Next Generation Antibody Therapeutics Market Drivers 15
2.3.3 Next Generation Antibody Therapeutics Market Challenges and Restraints 16
3 Competition Landscape by Key Players 17
3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue 17
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2017-2022) 17
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2017-2022) 18
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 19
3.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue 21
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio 22
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI) 22
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2021 23
3.5 Next Generation Antibody Therapeutics Key Players Head office and Area Served 23
3.6 Key Players Next Generation Antibody Therapeutics Product Solution and Service 24
3.7 Date of Enter into Next Generation Antibody Therapeutics Market 24
3.8 Mergers & Acquisitions, Expansion Plans 25
4 Next Generation Antibody Therapeutics Breakdown Data by Type 26
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2017-2022) 26
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2023-2028) 27
5 Next Generation Antibody Therapeutics Breakdown Data by Application 28
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2017-2022) 28
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2023-2028) 29
6 North America 30
6.1 North America Next Generation Antibody Therapeutics Market Size (2017-2028) 30
6.2 North America Next Generation Antibody Therapeutics Market Size by Type 30
6.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 30
6.2.2 North America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 31
6.2.3 North America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 31
6.3 North America Next Generation Antibody Therapeutics Market Size by Application 32
6.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 32
6.3.2 North America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 32
6.3.3 North America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 33
6.4 North America Next Generation Antibody Therapeutics Market Size by Country 33
6.4.1 North America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 33
6.4.2 North America Next Generation Antibody Therapeutics Market Share by Country (2023-2028) 34
6.4.3 United States 35
6.4.4 Canada 35
6.4.5 Mexico 36
7 Europe 37
7.1 Europe Next Generation Antibody Therapeutics Market Size (2017-2028) 37
7.2 Europe Next Generation Antibody Therapeutics Market Size by Type 37
7.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 37
7.2.2 Europe Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 38
7.2.3 Europe Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 38
7.3 Europe Next Generation Antibody Therapeutics Market Size by Application 39
7.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 39
7.3.2 Europe Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 39
7.3.3 Europe Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 40
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country 40
7.4.1 Europe Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 40
7.4.2 Europe Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 41
7.4.3 Germany 42
7.4.4 France 42
7.4.5 U.K. 43
7.4.6 Italy 43
7.4.7 Spain 44
8 Asia-Pacific 45
8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2017-2028) 45
8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type 45
8.2.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 45
8.2.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 46
8.2.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 46
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application 47
8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 47
8.3.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 47
8.3.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 48
8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region 48
8.4.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2017-2022) 48
8.4.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2023-2028) 49
8.4.3 China 50
8.4.4 Japan 50
8.4.5 South Korea 51
8.4.6 Southeast Asia 51
8.4.7 India 52
9 South America 53
9.1 South America Next Generation Antibody Therapeutics Market Size (2017-2028) 53
9.2 South America Next Generation Antibody Therapeutics Market Size by Type 53
9.2.1 South America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 53
9.2.2 South America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 54
9.2.3 South America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 54
9.3 South America Next Generation Antibody Therapeutics Market Size by Application 55
9.3.1 South America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 55
9.3.2 South America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 55
9.3.3 South America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 56
9.4 South America Next Generation Antibody Therapeutics Market Size by Country 56
9.4.1 South America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 56
9.4.2 South America Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 57
9.4.3 Brazil 58
9.4.4 Argentina 58
10 Middle East & Africa 59
10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2017-2028) 59
10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type 59
10.2.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 59
10.2.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 60
10.2.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 60
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application 61
10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 61
10.3.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 61
10.3.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 62
10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country 62
10.4.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 62
10.4.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 63
10.4.3 Middle East 64
10.4.4 Africa 64
11 Key Players Profiles 65
11.1 Roche 65
11.1.1 Roche Company Details 65
11.1.2 Roche Business Overview 65
11.1.3 Roche Next Generation Antibody Therapeutics Introduction 66
11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 69
11.1.5 Roche Recent Development 70
11.2 Amgen 70
11.2.1 Amgen Company Details 70
11.2.2 Amgen Business Overview 71
11.2.3 Amgen Next Generation Antibody Therapeutics Introduction 71
11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 72
11.2.5 Amgen Recent Development 73
11.3 Takeda 74
11.3.1 Takeda Company Details 74
11.3.2 Takeda Business Overview 74
11.3.3 Takeda Next Generation Antibody Therapeutics Introduction 74
11.3.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 76
11.3.5 Takeda Recent Development 77
11.4 Pfizer 78
11.4.1 Pfizer Company Details 78
11.4.2 Pfizer Business Overview 78
11.4.3 Pfizer Next Generation Antibody Therapeutics Introduction 79
11.4.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 80
11.4.5 Pfizer Recent Development 81
11.5 Seagen Inc. 81
11.5.1 Seagen Inc. Company Details 81
11.5.2 Seagen Inc. Business Overview 82
11.5.3 Seagen Inc. Next Generation Antibody Therapeutics Introduction 82
11.5.4 Seagen Inc. Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 84
11.5.5 Seagen Inc. Recent Development 85
11.6 Astellas 85
11.6.1 Astellas Company Details 85
11.6.2 Astellas Business Overview 86
11.6.3 Astellas Next Generation Antibody Therapeutics Introduction 86
11.6.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 87
11.6.5 Astellas Recent Development 87
11.7 Daiichi Sankyo 88
11.7.1 Daiichi Sankyo Company Details 88
11.7.2 Daiichi Sankyo Business Overview 88
11.7.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction 89
11.7.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 91
11.7.5 Daiichi Sankyo Recent Development 91
11.8 Immunomedics (Gilead) 92
11.8.1 Immunomedics (Gilead) Company Details 92
11.8.2 Immunomedics (Gilead) Business Overview 92
11.8.3 Immunomedics (Gilead) Next Generation Antibody Therapeutics Introduction 93
11.8.4 Immunomedics (Gilead) Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 93
11.8.5 Immunomedics (Gilead) Recent Development 94
11.9 GSK 94
11.9.1 GSK Company Details 94
11.9.2 GSK Business Overview 95
11.9.3 GSK Next Generation Antibody Therapeutics Introduction 95
11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 96
11.9.5 GSK Recent Development 96
11.10 Immunocore 97
11.10.1 Immunocore Company Details 97
11.10.2 Immunocore Business Overview 97
11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction 98
11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 98
11.10.5 Immunocore Recent Development 99
11.11 ADC Therapeutics SA 99
11.11.1 ADC Therapeutics SA Company Details 99
11.11.2 ADC Therapeutics SA Business Overview 100
11.11.3 ADC Therapeutics SA Next Generation Antibody Therapeutics Introduction 100
11.11.4 ADC Therapeutics SA Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 101
11.11.5 ADC Therapeutics SA Recent Development 102
12 Analyst's Viewpoints/Conclusions 103
13 Appendix 104
13.1 Research Methodology 104
13.1.1 Methodology/Research Approach 104
13.1.2 Data Source 107
13.2 Disclaimer 110
13.3 Author Details 110

 

ページTOPに戻る


 

Summary

Market Analysis and Insights: Global Next Generation Antibody Therapeutics Market
Due to the COVID-19 pandemic and Spain-Ukraine War Influence, the global market for Next Generation Antibody Therapeutics estimated at US$ 12257.15 million in the year 2022, is projected to reach a revised size of US$ 39442.45 million by 2028, growing at a CAGR of 21.51% during the forecast period 2022-2028.

The USA market for Next Generation Antibody Therapeutics is estimated to increase from US$ 7362.24 million in 2022 to reach US$ 20256.78 million by 2028, at a CAGR of 18.38% during the forecast period of 2022-2028.
The Europe market for Next Generation Antibody Therapeutics is estimated to increase from US$ 2284.07 million in 2022 to reach US$ 9019.50 million by 2028, at a CAGR of 25.72% during the forecast period of 2022 through 2028.
The Japan market for Next Generation Antibody Therapeutics is estimated to increase from US$ 1154.2 million in 2022 to reach US$ 3337.61 million by 2028, at a CAGR of 19.36% during the forecast period of forecast years.
The global key companies of Next Generation Antibody Therapeutics include Roche, Amgen, Takeda, Pfizer, Seagen Inc., ADC Therapeutics SA, Astellas, Daiichi Sankyo, and Immunomedics (Gilead), etc. In 2021, the global top five players had a share approximately 88.78% in terms of revenue.

Report Includes
This report presents an overview of global market for Next Generation Antibody Therapeutics market size. Analyses of the global market trends, with historic market revenue data for 2017 - 2021, estimates for 2022, and projections of CAGR through 2028.
This report researches the key producers of Next Generation Antibody Therapeutics, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Next Generation Antibody Therapeutics, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, Japan, China, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Next Generation Antibody Therapeutics revenue, market share and industry ranking of main companies, data from 2017 to 2022. Identification of the major stakeholders in the global Next Generation Antibody Therapeutics market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2017 to 2028. Evaluation and forecast the market size for Next Generation Antibody Therapeutics revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Roche, Amgen, Takeda, Pfizer, Seagen Inc., ADC Therapeutics SA, Astellas, Daiichi Sankyo, and Immunomedics (Gilead), etc.

By Company
Roche
Amgen
Pfizer
Takeda
Daiichi Sankyo
Seagen
Astellas
Immunomedics
GSK
Immunocore
ADC Therapeutics

Segment by Type
Antibody Drug Conjugate (ADC)
Bispecific Antibody (BsAb)

Segment by Application
Cancer
Haemophilia
Other Non-Cancer Diseases

By Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Southeast Asia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Spain
Rest of Europe
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Middle East
Africa

Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Next Generation Antibody Therapeutics in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Next Generation Antibody Therapeutics companies competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by Type, by Application and by country, revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, revenue for each segment.
Chapter 8: Asia Pacific by Type, by Application and by region, revenue for each segment.
Chapter 9: South America by Type, by Application and by country, revenue for each segment.
Chapter 10: Middle East and Africa by Type, by Application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Next Generation Antibody Therapeuticsrevenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions



ページTOPに戻る


Table of Contents

1 Report Overview 1
1.1 Study Scope 1
1.2 Market Analysis by Type 1
1.2.1 Global Next Generation Antibody Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028 1
1.2.2 Antibody Drug Conjugate (ADC) 3
1.2.3 Bispecific Antibody (BsAb) 3
1.3 Market by Application 4
1.3.1 Global Next Generation Antibody Therapeutics Market Share by Application: 2017 VS 2021 VS 2028 5
1.3.2 Cancer 6
1.3.3 Haemophilia 7
1.3.4 Other Non-Cancer Diseases 8
1.4 Study Objectives 9
1.5 Years Considered 10
2 Global Growth Trends 11
2.1 Global Next Generation Antibody Therapeutics Market Perspective (2017-2028) 11
2.2 Next Generation Antibody Therapeutics Growth Trends by Region 12
2.2.1 Next Generation Antibody Therapeutics Market Size by Region: 2017 VS 2021 VS 2028 12
2.2.2 Next Generation Antibody Therapeutics Historic Market Size by Region (2017-2022) 13
2.2.3 Next Generation Antibody Therapeutics Forecasted Market Size by Region (2023-2028) 14
2.3 Next Generation Antibody Therapeutics Market Dynamics 15
2.3.1 Next Generation Antibody Therapeutics Industry Trends 15
2.3.2 Next Generation Antibody Therapeutics Market Drivers 15
2.3.3 Next Generation Antibody Therapeutics Market Challenges and Restraints 16
3 Competition Landscape by Key Players 17
3.1 Global Top Next Generation Antibody Therapeutics Players by Revenue 17
3.1.1 Global Top Next Generation Antibody Therapeutics Players by Revenue (2017-2022) 17
3.1.2 Global Next Generation Antibody Therapeutics Revenue Market Share by Players (2017-2022) 18
3.2 Global Next Generation Antibody Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3) 19
3.3 Players Covered: Ranking by Next Generation Antibody Therapeutics Revenue 21
3.4 Global Next Generation Antibody Therapeutics Market Concentration Ratio 22
3.4.1 Global Next Generation Antibody Therapeutics Market Concentration Ratio (CR5 and HHI) 22
3.4.2 Global Top 10 and Top 5 Companies by Next Generation Antibody Therapeutics Revenue in 2021 23
3.5 Next Generation Antibody Therapeutics Key Players Head office and Area Served 23
3.6 Key Players Next Generation Antibody Therapeutics Product Solution and Service 24
3.7 Date of Enter into Next Generation Antibody Therapeutics Market 24
3.8 Mergers & Acquisitions, Expansion Plans 25
4 Next Generation Antibody Therapeutics Breakdown Data by Type 26
4.1 Global Next Generation Antibody Therapeutics Historic Market Size by Type (2017-2022) 26
4.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Type (2023-2028) 27
5 Next Generation Antibody Therapeutics Breakdown Data by Application 28
5.1 Global Next Generation Antibody Therapeutics Historic Market Size by Application (2017-2022) 28
5.2 Global Next Generation Antibody Therapeutics Forecasted Market Size by Application (2023-2028) 29
6 North America 30
6.1 North America Next Generation Antibody Therapeutics Market Size (2017-2028) 30
6.2 North America Next Generation Antibody Therapeutics Market Size by Type 30
6.2.1 North America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 30
6.2.2 North America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 31
6.2.3 North America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 31
6.3 North America Next Generation Antibody Therapeutics Market Size by Application 32
6.3.1 North America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 32
6.3.2 North America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 32
6.3.3 North America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 33
6.4 North America Next Generation Antibody Therapeutics Market Size by Country 33
6.4.1 North America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 33
6.4.2 North America Next Generation Antibody Therapeutics Market Share by Country (2023-2028) 34
6.4.3 United States 35
6.4.4 Canada 35
6.4.5 Mexico 36
7 Europe 37
7.1 Europe Next Generation Antibody Therapeutics Market Size (2017-2028) 37
7.2 Europe Next Generation Antibody Therapeutics Market Size by Type 37
7.2.1 Europe Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 37
7.2.2 Europe Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 38
7.2.3 Europe Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 38
7.3 Europe Next Generation Antibody Therapeutics Market Size by Application 39
7.3.1 Europe Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 39
7.3.2 Europe Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 39
7.3.3 Europe Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 40
7.4 Europe Next Generation Antibody Therapeutics Market Size by Country 40
7.4.1 Europe Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 40
7.4.2 Europe Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 41
7.4.3 Germany 42
7.4.4 France 42
7.4.5 U.K. 43
7.4.6 Italy 43
7.4.7 Spain 44
8 Asia-Pacific 45
8.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size (2017-2028) 45
8.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type 45
8.2.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 45
8.2.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 46
8.2.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 46
8.3 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application 47
8.3.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 47
8.3.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 47
8.3.3 Asia-Pacific Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 48
8.4 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region 48
8.4.1 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2017-2022) 48
8.4.2 Asia-Pacific Next Generation Antibody Therapeutics Market Size by Region (2023-2028) 49
8.4.3 China 50
8.4.4 Japan 50
8.4.5 South Korea 51
8.4.6 Southeast Asia 51
8.4.7 India 52
9 South America 53
9.1 South America Next Generation Antibody Therapeutics Market Size (2017-2028) 53
9.2 South America Next Generation Antibody Therapeutics Market Size by Type 53
9.2.1 South America Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 53
9.2.2 South America Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 54
9.2.3 South America Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 54
9.3 South America Next Generation Antibody Therapeutics Market Size by Application 55
9.3.1 South America Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 55
9.3.2 South America Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 55
9.3.3 South America Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 56
9.4 South America Next Generation Antibody Therapeutics Market Size by Country 56
9.4.1 South America Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 56
9.4.2 South America Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 57
9.4.3 Brazil 58
9.4.4 Argentina 58
10 Middle East & Africa 59
10.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size (2017-2028) 59
10.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type 59
10.2.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2017-2022) 59
10.2.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Type (2023-2028) 60
10.2.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Type (2017-2028) 60
10.3 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application 61
10.3.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2017-2022) 61
10.3.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Application (2023-2028) 61
10.3.3 Middle East & Africa Next Generation Antibody Therapeutics Market Share by Application (2017-2028) 62
10.4 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country 62
10.4.1 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2017-2022) 62
10.4.2 Middle East & Africa Next Generation Antibody Therapeutics Market Size by Country (2023-2028) 63
10.4.3 Middle East 64
10.4.4 Africa 64
11 Key Players Profiles 65
11.1 Roche 65
11.1.1 Roche Company Details 65
11.1.2 Roche Business Overview 65
11.1.3 Roche Next Generation Antibody Therapeutics Introduction 66
11.1.4 Roche Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 69
11.1.5 Roche Recent Development 70
11.2 Amgen 70
11.2.1 Amgen Company Details 70
11.2.2 Amgen Business Overview 71
11.2.3 Amgen Next Generation Antibody Therapeutics Introduction 71
11.2.4 Amgen Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 72
11.2.5 Amgen Recent Development 73
11.3 Takeda 74
11.3.1 Takeda Company Details 74
11.3.2 Takeda Business Overview 74
11.3.3 Takeda Next Generation Antibody Therapeutics Introduction 74
11.3.4 Takeda Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 76
11.3.5 Takeda Recent Development 77
11.4 Pfizer 78
11.4.1 Pfizer Company Details 78
11.4.2 Pfizer Business Overview 78
11.4.3 Pfizer Next Generation Antibody Therapeutics Introduction 79
11.4.4 Pfizer Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 80
11.4.5 Pfizer Recent Development 81
11.5 Seagen Inc. 81
11.5.1 Seagen Inc. Company Details 81
11.5.2 Seagen Inc. Business Overview 82
11.5.3 Seagen Inc. Next Generation Antibody Therapeutics Introduction 82
11.5.4 Seagen Inc. Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 84
11.5.5 Seagen Inc. Recent Development 85
11.6 Astellas 85
11.6.1 Astellas Company Details 85
11.6.2 Astellas Business Overview 86
11.6.3 Astellas Next Generation Antibody Therapeutics Introduction 86
11.6.4 Astellas Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 87
11.6.5 Astellas Recent Development 87
11.7 Daiichi Sankyo 88
11.7.1 Daiichi Sankyo Company Details 88
11.7.2 Daiichi Sankyo Business Overview 88
11.7.3 Daiichi Sankyo Next Generation Antibody Therapeutics Introduction 89
11.7.4 Daiichi Sankyo Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 91
11.7.5 Daiichi Sankyo Recent Development 91
11.8 Immunomedics (Gilead) 92
11.8.1 Immunomedics (Gilead) Company Details 92
11.8.2 Immunomedics (Gilead) Business Overview 92
11.8.3 Immunomedics (Gilead) Next Generation Antibody Therapeutics Introduction 93
11.8.4 Immunomedics (Gilead) Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 93
11.8.5 Immunomedics (Gilead) Recent Development 94
11.9 GSK 94
11.9.1 GSK Company Details 94
11.9.2 GSK Business Overview 95
11.9.3 GSK Next Generation Antibody Therapeutics Introduction 95
11.9.4 GSK Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 96
11.9.5 GSK Recent Development 96
11.10 Immunocore 97
11.10.1 Immunocore Company Details 97
11.10.2 Immunocore Business Overview 97
11.10.3 Immunocore Next Generation Antibody Therapeutics Introduction 98
11.10.4 Immunocore Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 98
11.10.5 Immunocore Recent Development 99
11.11 ADC Therapeutics SA 99
11.11.1 ADC Therapeutics SA Company Details 99
11.11.2 ADC Therapeutics SA Business Overview 100
11.11.3 ADC Therapeutics SA Next Generation Antibody Therapeutics Introduction 100
11.11.4 ADC Therapeutics SA Revenue in Next Generation Antibody Therapeutics Business (2017-2022) 101
11.11.5 ADC Therapeutics SA Recent Development 102
12 Analyst's Viewpoints/Conclusions 103
13 Appendix 104
13.1 Research Methodology 104
13.1.1 Methodology/Research Approach 104
13.1.2 Data Source 107
13.2 Disclaimer 110
13.3 Author Details 110

 

ページTOPに戻る

ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。

webからのご注文・お問合せはこちらのフォームから承ります

本レポートと同分野(抗生物薬)の最新刊レポート

本レポートと同じKEY WORD(antibody)の最新刊レポート


よくあるご質問


QYResearch社はどのような調査会社ですか?


QYリサーチ(QYResearch)は幅広い市場を対象に調査・レポート出版を行う、中国に本社をおく調査会社です。   QYResearchでは年間数百タイトルの調査レポートを出版しています。... もっと見る


調査レポートの納品までの日数はどの程度ですか?


在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
但し、一部の調査レポートでは、発注を受けた段階で内容更新をして納品をする場合もあります。
発注をする前のお問合せをお願いします。


注文の手続きはどのようになっていますか?


1)お客様からの御問い合わせをいただきます。
2)見積書やサンプルの提示をいたします。
3)お客様指定、もしくは弊社の発注書をメール添付にて発送してください。
4)データリソース社からレポート発行元の調査会社へ納品手配します。
5) 調査会社からお客様へ納品されます。最近は、pdfにてのメール納品が大半です。


お支払方法の方法はどのようになっていますか?


納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
お客様よりデータリソース社へ(通常は円払い)の御振り込みをお願いします。
請求書は、納品日の日付で発行しますので、翌月最終営業日までの当社指定口座への振込みをお願いします。振込み手数料は御社負担にてお願いします。
お客様の御支払い条件が60日以上の場合は御相談ください。
尚、初めてのお取引先や個人の場合、前払いをお願いすることもあります。ご了承のほど、お願いします。


データリソース社はどのような会社ですか?


当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
世界各国の「市場・技術・法規制などの」実情を調査・収集される時には、データリソース社にご相談ください。
お客様の御要望にあったデータや情報を抽出する為のレポート紹介や調査のアドバイスも致します。



詳細検索

このレポートへのお問合せ

03-3582-2531

電話お問合せもお気軽に

 

2024/11/14 10:27

156.77 円

166.04 円

201.95 円

ページTOPに戻る